GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Days Inventory

Coherus BioSciences (Coherus BioSciences) Days Inventory

: 69.81 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Coherus BioSciences's Average Total Inventories for the three months ended in Dec. 2023 was $64.7 Mil. Coherus BioSciences's Cost of Goods Sold for the three months ended in Dec. 2023 was $84.6 Mil. Hence, Coherus BioSciences's Days Inventory for the three months ended in Dec. 2023 was 69.81.

The historical rank and industry rank for Coherus BioSciences's Days Inventory or its related term are showing as below:

CHRS' s Days Inventory Range Over the Past 10 Years
Min: 116.39   Med: 199.04   Max: 261.83
Current: 129.28

During the past 12 years, Coherus BioSciences's highest Days Inventory was 261.83. The lowest was 116.39. And the median was 199.04.

CHRS's Days Inventory is ranked better than
66.56% of 649 companies
in the Biotechnology industry
Industry Median: 191.36 vs CHRS: 129.28

Coherus BioSciences's Days Inventory declined from Dec. 2022 (213.67) to Dec. 2023 (69.81).

Inventory Turnover measures how fast the company turns over its inventory within a year. Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2023 was 1.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Coherus BioSciences's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.71.


Coherus BioSciences Days Inventory Historical Data

The historical data trend for Coherus BioSciences's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.53 261.83 259.45 199.04 116.39

Coherus BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Inventory Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 213.67 238.47 208.21 182.44 69.81

Competitive Comparison

For the Biotechnology subindustry, Coherus BioSciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences Days Inventory Distribution

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Days Inventory distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Days Inventory falls into.



Coherus BioSciences Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Coherus BioSciences's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (38.791 + 62.605) / 2 ) / 158.992*365
=50.698 / 158.992*365
=116.39

Coherus BioSciences's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (66.783 + 62.605) / 2 ) / 84.567*365 / 4
=64.694 / 84.567*365 / 4
=69.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coherus BioSciences  (NAS:CHRS) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Coherus BioSciences's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Coherus BioSciences Days Inventory Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (Coherus BioSciences) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009